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Mesenchymal stem cells of 
systemic sclerosis patients, derived 
from different sources, show a 
profibrotic microRNA profiling
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Francesco Carubbi1, Giuliana Guggino3, Andrea Bianchi4, Antinisca Di Marco  2, 
Francesco Ciccia3, edoardo Alesse2 & Roberto Giacomelli1
Systemic Sclerosis (SSc) is a disease with limited therapeutic possibilities. Mesenchymal stem cells 
(MSCs)-therapy could be a promising therapeutic option, however the ideal MSCs source has not yet 
been found. To address this problem, we perform comparison between bone marrow (BM)-MSCs and 
adipose (A)-MSCs, by the miRs expression profile, to identify the gene modulation in these two MSCs 
source. MicroRNAs (miRs) are RNAs sequences, regulating gene expression and MSCs, derived from 
different tissues, may differently respond to the SSc microenvironment. The miRs array was used for 
the miRs profiling and by DIANA-mirPath tool we identified the biological functions of the dysregulated 
miRs. In SSc-BM-MSCs, 6 miRs were significantly down-regulated and 4 miRs up-regulated. In SSc-A-
MSCs, 11 miRs were significantly down-regulated and 3 miRs up-regulated. Interestingly, in both the 
sources, the involved pathways included the senescence mechanisms and the pro-fibrotic behaviour. 
Furthermore, both the MSCs sources showed potential compensatory ability. A deeper knowledge of 
this miRs signature might give more information about some pathogenic steps of the disease and in the 
same time clarify the possible therapeutic role of autologous MSCs in the regenerative therapy in SSc.
SSc is a complex multisystem disorder, characterised by microvascular damage, dysregulation of innate and 
adaptive immunity, and generalized fibrosis in the skin and multiple organs1–8, such as lungs9, gastrointestinal 
tract10, kidneys11 and heart12. Due to the heterogeneity, in terms of extent, severity, and rate of progression, the 
optimal therapeutic interventions for SSc is still lacking and, to date, no disease-modifying agents are available13 
and future options include regenerative therapies by using stem cells. Among these cells, MSCs are a subset of 
multipotent cells, which may be identified in a large variety of tissues, including bone marrow, placenta, umbil-
ical cord, adipose tissue, teeth and menstrual fluid, largely involved in the reparative function after damage, 
thus suggesting their potential role in regenerative medicine14–18. Considering the pleiotropic effects of MSC, 
displaying immunomodulatory, angiogenic and antifibrotic capabilities, MSC-based therapy could counter-
act the three main pathogenic axes of SSc17–19. On these bases, MSCs isolated from SSc patients (SSc-MSCs) 
were largely studied and it is largely accepted that SSc-BM-MSCs strongly differentiate toward myofibroblasts, 
mainly after cross-talking with endothelial cells from SSc patients, thus confirming the link between the early 
vascular involvement of SSc and subsequent fibrosis3. Furthermore, SSc-BM-MSCs exhibit increased expres-
sion of senescent marker but maintaining immunosuppressive and immune-regulatory functions20. As far as 
SSc-A-MSCs are concerned, available literature did not show any alterations in both phenotype and differentiative 
potential14 between cells obtained from SSc patients and controls, although a decrease of proliferative activity 
as well as migration capacity have been reported21. On these bases, recent data suggest that, independent of the 
source, MSCs from SSc patients may be pre-committed in their differentiative behaviour toward myofibroblast, 
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conditioned by both the cytokines and the metabolic milieu, specific of the disease3,18,22,23. These data partially 
mirror what showed in another autoimmune disease, the Systemic Lupus Erythematosus (SLE)24, and lead to 
speculate that in the field of regenerative medicine, an allogeneic rather than an autologous MSC-based therapy 
might be preferable for future treatments. Furthermore, it has been shown that allogenic MSCs infusion is a safe 
therapy for patients with autoimmune disease, including SSc patients25. In this developing setting, it is mandatory 
to better characterise the specific profile of MSCs derived from different sources, to understand if autologous cells 
may be used in SSc patients, for regenerative medicine. At present, the large majority of the molecular actors, con-
trolling MSCs functions, are still largely unknown and recently a great importance has been recognised at a new 
class of non-coding RNAs, the so-called microRNAs (miRs), and the expression of characteristic miRs profiles 
has been implicated in the control of the normal development of specific system such as the cardiovascular tree, 
as well as in the pathogenesis of autoimmune diseases and cancer26. It is well known that, miRs down-regulation 
may result in a loss of their ability to inhibit target mRNA and, on the contrary, the miR upregulation may lead 
to an increase of target mRNA inhibition. MiRs control the gene expression by complementary base pairing with 
specific sites on the 3′-untranslated regions of their target gene mRNAs27. In the last years, specific miRs profiles, 
associated with different diseases, have been tested in in silico studies, to identify the panel of genes potentially 
controlled, and this tissue- and disease-specific miRs profiles often resulted more informative and discriminant 
than mRNA profiles26.
Thus, we used the miRs array approach to define the profile of MSCs derived from different sources in SSc 
patients, in order to assess the possible molecular differences between these cells. Furthermore, the possibility 
to predict different cells behaviours specifically related to the tissues used as source, was approached in silico. 
A better knowledge of phenotype and functions of these cells, associated with their stem plasticity, should be 
considered the first basic step to plan and develop any MSC-based therapy, and also to better understand the 
preliminary results obtained in the small case series of SSc patients treated with MSCs.
Results
Identification of miR expression profiling discriminating SSc-BM-MSCs and SSc-A-MSCs. The 
SSc-MSCs were isolated from SSc patients and the demographic and clinical characteristics of the patients are 
showed in Table 1.
To compare miRs expression patterns among the MSCs derived from different source, we analysed the miRs 
expression levels by comparing SSc-BM-MSCs with HC-BM-MSCs, and SSc-A-MSCs with HC-A-MSCs as 
well. For each group, three replicates were analysed, and their expression levels are represented in Fig. 1. Among 
the 754 miRs analysed, we focused our analysis on those significantly dysregulated (p < 0,05), displaying more 
than 2-fold hypo- or hyper-expression (whole expression data are shown in Supplementary S1). SSc-BM-MSCs, 
showed 6 significantly down-regulated miRs, with fold change less than 0,5 (hsa-miR-200b-3p, hsa-miR-642a-5p, 
hsa-miR-483-3p, hsa-miR-519b-3p, hsa-miR-875-5p, hsa-miR-489-3p), 4 significantly up-regulated miRs, show-
ing fold change higher than 2 (hsa-miR-10b-3p, hsa-miR-629-3p, hsa-miR-432-5p, hsa-miR-668-3p) and 5 miRs 
with less marked down- (fold change included between 0,584 and 0,767) or up- (fold change included between 
1,324 and 1,55) regulation (hsa-miR-432-3p, hsa-miR-30d-3p, hsa-miR-335-3p, hsa-miR-30e-3p, hsa-miR-
454-3p), when compared with HC-BM-MSCs. The SSc-A-MSCs showed 11 significantly down-regulated 
miRs, with fold change less than 0,5 (hsa-miR-218-5p, hsa-miR-135b-5p, hsa-miR-199b-5p, hsa-miR-204-5p, 
dme-mir-7, hsa-miR-500a-5p, hsa-miR-423-5p, hsa-miR-146a-5p, hsa-miR-708-5p, hsa-miR-155-5p, hsa-miR-
146b-5p), 3 significantly up-regulated miRs, with fold change higher than 2 (hsa-miR-1227-3p, hsa-miR-1225-3p, 
hsa-miR-1267) and 8 miRs (hsa-miR-185-5p, hsa-miR-10a-5p, hsa-miR-222-5p, hsa-miR-766-3p, hsa-miR-
1274A, hsa-miR-1271-5p, hsa-miR-27a-5p, hsa-miR-573) whose down- or up-regulation was less marked and 
included between 0,518 and 0,64 or 1,391 and 1,703, when compared with HC-A-MSCs (Table 2). Those results 
highlight 2 different miR profiles: Profile BM and Profile A, and the Venn diagram (Fig. 2) shows that the Profile 
BM and Profile A are characterized by totally different miRs expression.
MiRs target prediction analysis. In silico analysis, predicting the putative biological functions of the miRs, 
suggested their involvement in specific Kyoto Encyclopedia of Genes and Genomes (KEGG) signalling pathways. 
Sex/Age 
(yrs)
Disease duration at skin 
biopsy (years from RP)
MRSS/score at 
skin biopsy Autoantibodies ILD PAH SCR RP DU
F/45 <1 08/2 ANA/Scl-70 No No No Yes No
F/35 <1 10/1 ANA/Scl-70 No No No Yes Yes
F/31 <1 07/2 ANA/Scl-70 No No No Yes No
F/40 <1 10/2 ANA/Scl-70 No No No Yes No
F/43 <1 06/1 ANA/Scl-70 No No No Yes No
F/34 <1 09/2 ANA/Scl-70 No No No Yes No
Table 1. Clinical and demographic features of the 6 diffuse SSc patients. RP = Raynaud’s phenomenon; 
MRSS = modified Rodnan skin thickness score (maximum possible score 51); ILD: interstitial lung disease; 
ANA = antinuclear antibodies; Scl-70 = anti topoisomerase; PAH = pulmonary arterial hypertension. 
SCR = scleroderma renal crisis. DU = digital ulcers. The internal organs involvement is referred to the time of 
biopsies.
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The KEGG database identifies significantly enriched metabolic pathways or signal transduction pathways from 
lists of candidate target genes and compares this enrichment with a reference background.
In the Profile BM, the 6 down-regulated miRs were implicated in 32 KEGG biological pathways (p value 
threshold 0,05). Among them, we focused the analysis on: Signalling Pathways Regulating Pluripotency Of 
Stem Cells (hsa04550, p = 0,009), MAPK Signalling Pathway (hsa04010, p = 0,01), HIF-1 Signalling Pathway 
(hsa04066, p = 0,01), TGF-beta Signalling Pathway (hsa04350, p = 0,02), p53 Signalling Pathway (hsa04115, 
p = 0,03), PI3K-Akt Signalling Pathway (hsa04151, p = 0,04). The 4 miRs up-regulated in Profile BM were 
involved in 1 KEGG pathway (p value threshold 0,05), the ECM-Receptor Interaction (hsa04512; p = 2,1 × 10−11).
In the Profile A, the 11 down-regulated miRs were identified in 18 KEGG pathways (p-value threshold 0,05), 
including: TGF-beta Signalling Pathway (hsa04350, p = 2 × 10−5), Signalling Pathways Regulating Pluripotency 
Of Stem Cells (hsa04550, p = 0,001), Regulation Of Actin Cytoskeleton (hsa04810, p = 0,008) and Wnt Signalling 
Pathway (hsa04310, p = 0,03). Furthermore, the 3 up-regulated miRs were involved in 1 KEGG biological process, 
the Thyroid Hormone Signalling Pathway (hsa04919, p = 0,007). Each pathway was reported in Table 3.
Experimental validated target prediction. Using microT-CDS, we reported in Supplementary S2, 
all the predicted gene targeting the miRs including in the selected pathways. Furthermore, we restricted our 
investigation only on target genes, experimentally validated. None validated target gene has been found for miR 
up-regulated in both Profile BM and A. As far as the miRs down regulated in the Profile BM are concerned, 
the target genes experimentally validated were reported in Table 4. MiRs-200b-3b targets the validated genes: 
SMAD2/5, KLF4, CRKL, RASA2, ELK4, PAK2, TAOK1, JUN, RPS6KA3, RAP1B, DUSP1, PLCG1, FLT1, EIF4E2, 
PPP2R1B, ZMAT3, CDK2, PMAIP1, CCNE2, SESN1, SIAH1, PPP2R5E, YWHAG, BRCA1, PTK2, ITGAV, 
EFNA1, KDR, FLT1; miR-519a-3p targets HSPA8 and PTEN and the miR-483-3p targets ZAK. In the Profile 
A, the down regulated miRs are involved as follow: miR-155-5p targets SP1, JARID2, GSK3B, KAT6A, KRAS, 
PAK2/7, FGF9, CHD8 and CSNK1A1; miR-500a-5p targets RPS6KB1 and TBL1XR1; miR-146a-5p targets RBL1 
and SMAD4; miR-146b-5p interacts with RBL1 and ARPC5; the miR-204-5p with FZD1, MEIS1 and CCND2; 
miR-423-5p targets ARPC5, ITGA5 and PRKACA; miR-135b-5p: SMARCAD1 and WASF2; miR-218-5p targets 
PPP1CC, ACTN1 and SENP2; the hsa-miR-199b-5p targets GIT1; and finally, the miR-708-5p targets: IQGAP1 
and DIAPH1.
The results obtained were included in a Neo4J graph database28 to provide a graphical representation of 
miRNAs-targets interactions (Fig. 3). This graphical representation highlighted that both the Profiles shared, 2 
important pathways in this clinical setting: the TGF-beta Signalling Pathway and Signalling Pathways Regulating 
Pluripotency Of Stem Cells.
Discussion
Considering the regenerative potential of MSC, displaying immunomodulatory, angiogenic and antifibrotic 
capabilities, MSC-based therapy could counteract the three main pathogenic axes of SSc17,22,29,30, a clinical set-
ting lacking effective therapy. This is the first paper reporting in silico comparative analysis of miRs profile of 
MSCs isolated from different sources (BM and A) of SSc patients. We showed that, independent from the source, 
Figure 1. MiRs volcano plots. MiRs volcano plots of SSc-BM-MSC (A,B) and SSc-A-SSC (C,D). MicroRNAs’ 
distribution, obtained from TaqMan array human microRNA set A (in A,C) and set B (in B,D) was reported. In 
green are reported all the miRs down regulated, in red all the miRs up-regulated. Analyses were performed by 
using Expression Suite software. Y axis: p value (−log10), p = 0,05 threshold in blue. X axis: fold change (log2), 
black vertical lines indicate 0,5 (left) and 2 (right) fold change.
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an upregulation of the pathways regulating the senescence and the profibrotic phenotype, may be observed 
in the MSCs of patients affected by SSc, a disease characterized by diffuse fibrosis of skin and internal organs. 
Furthermore, both BM- and A-SSc-MSCs display a down regulation of the miRs controlling the genes related 
to cells survival, thus suggesting the ability of these cells to protect themselves, activating specific pathways in 
response to the critical conditions, found in the scleroderma microenvironment31,32, such as hypoxia and inflam-
mation14,33. At present, one third of the clinical trials using engrafting MSCs are designed to evaluate their ther-
apeutic role in autoimmune diseases (for the latest update, see ttp://www.clinicaltrials.gov). Considering the 
immunomodulatory, pro-angiogenic and antifibrotic capabilities of MSCs, their transplant may have a potential 
application in cell-based therapies for SSc and results obtained in preclinical models3,6,14,19,20,23, as well as the few 
cases reported in the SSc34,35 seem very promising. However, many in vitro experiments showed some differences 
in the biologic functions of SSc-MSCs, deriving from different tissues3,6,22,23. These data raised some concern 
about their efficacy in transplant strategy, since the profibrotic signature of SSc-MSCs may thwart their potential 
beneficial effects and suggested further refinements in the molecular and genetic knowledge of MSCs.
Profile BM: SSc-BM-MSCs vs HC-BM-MSCs
RQ: relative quantification pmiRs (miRbase ID)
hsa-miR-200b-3p 0,126 0,015
hsa-miR-642a-5p 0,198 0,048
hsa-miR-483-3p 0,242 0,045
hsa-miR-519b-3p 0,307 0,024
hsa-miR-875-5p 0,377 0,032
hsa-miR-489-3p 0,456 0,028
hsa-miR-432-3p 0,584 0,041
hsa-miR-30d-3p 0,673 0,035
hsa-miR-335-3p 0,767 0,003
hsa-miR-30e-3p 1,324 0,016
hsa-miR-454-3p 1,550 0,038
hsa-miR-10b-3p 2,351 0,044
hsa-miR-629-3p 2,361 0,008
hsa-miR-432-5p 2,500 0,028
hsa-miR-668-3p 15,389 0,048
Profile A: SSc-A-MSCs vs HC-A-MSCs
RQ: relative quantification p
miRs (miRbase ID)
hsa-miR-218-5p 0,226 0,037
hsa-miR-135b-5p 0,250 0,008
hsa-miR-199b-5p 0,328 0,013
hsa-miR-204-5p 0,329 0,03
dme-mir-7 0,393 0,038
hsa-miR-500a-5p 0,406 0,044
hsa-miR-423-5p 0,436 0,032
hsa-miR-146a-5p 0,439 0,046
hsa-miR-708-5p 0,458 0,042
hsa-miR-155-5p 0,459 0,034
hsa-miR-146b-5p 0,480 0,047
hsa-miR-185-5p 0,518 0,029
hsa-miR-10a-5p 0,557 0,029
hsa-miR-222-5p 0,620 0,02
hsa-miR-766-3p 0,640 0,03
hsa-miR-1274A 1,391 0,019
hsa-miR-1271-5p 1,480 0,044
hsa-miR-27a-5p 1,621 0,037
hsa-miR-573 1,703 0,049
hsa-miR-1227-3p 2,445 0,016
hsa-miR-1225-3p 2,608 0,014
hsa-miR-1267 2,742 0,024
Table 2. Dysregulated miRs in Profile BM and A. List of significantly dysregulated miRs in Profile BM and A. 
Significant miRs expression changes were identified using a threshold of p < 0,05 (p value calculation based on 
2−dCt).
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It has been reported that long‐term culture evokes continuous changes in MSCs: proliferation rate decays, the 
cell size increases, differentiation potential is affected, chromosomal instabilities may arise, and molecular changes 
are acquired. In fact, early passage MSCs were preferred for therapeutic efficacy in many clinical trials36 and, on 
this basis, we choose to characterize the miR profiling of P3 MSCs, providing a profiling of in vitro expanded 
MSCs at the time in which they may be used for transplantation. We observed that P3 SSc-BM-MSCs expressed 
6 miRs significantly down-regulated and 4 miRs significantly up-regulated when compared with HC-BM-MSCs. 
As far as, A-tissue is concerned, P3 SSc-MSCs expressed 11 down-regulated miRs and 3 up-regulated, when 
compared with HC. These data identified 2 different profiles and of note, the miRs listed in one Profile were not 
present in the other Profile. This datum confirms that miRs constitute a family of regulators for gene expression, 
which may be largely tissue-dependent37.
To assess the biological significance of miRs listed in both Profiles, we relied on in silico analysis for predicting 
potential miRs targets. In both Profiles, we observed two specific patterns and by the “Diana miRPath” software, 
we try to identify the signalling pathways, significantly associated with each pattern in both Profiles.
In the Profile BM, 6 miRs were down-regulated, targeting 32 KEGG pathways, considering the high number of 
these pathways, we focused our discussion on the KEGG pathways that may play a specific relevance in SSc, such 
as “Signalling Pathways Regulating Pluripotency Of Stem Cells”, “MAPK Signalling Pathway”, “HIF-1 Signalling 
Pathway”, “TGF-Beta Signalling Pathway”, “P53 Signalling Pathway” And “PI3K-Akt Signalling Pathway”. The 
“Signalling Pathways Regulating Pluripotency Of Stem Cells” may involve transcription factors and their down-
stream target genes promoting self-renewal and pluripotency of stem cells. Using microT-CDS, among the val-
idated target genes of this pathway, we observed the genes regulating for: SMAD-2 and -5, thus suggesting a 
profibrotic signature of MSCs5 and KLF438,39, which is involved in the cellular senescence. The “MAPK Signalling 
Pathway” is involved in various cellular functions, including cell response to different stimulation. This path-
way includes several validated target genes: HSPA8, TAOK1, RPS6KA3 and PAK2, regulating the adaptation to 
different stress stimuli and cells survival29,40–42, and CRKL, promoting activities including cytoskeletal remod-
elling, cell motility, cell proliferation and mitosis38. Furthermore, several genes involved in this pathway display 
pro-apoptotic activity, such as ELK4, JUN, RASA2, DUSP1 and ZAK, and proliferation, such as RAP1B38.
The “HIF-1 Signalling Pathway” includes gene encoding proteins, mediating adaptive responses to nitric oxide 
and reduced oxygen availability, a common condition during SSc, in which a desertification of vascular tree is 
present, and it is not surprising to observe that the validated target genes for this pathway are: PLCG1, FLT1 and 
EIF4E2, which may mediate MSCs proliferation, angiogenesis and survival in hypoxia condition38,43,44, suggesting 
a compensatory mechanism in these patients. The “TGF-beta Signalling Pathway” includes genes with a specific 
relevance during fibrotic process. The experimentally validated target genes are: SMAD2 and 5 and PPP2R1B, 
promoting the TGF-beta signalling5,45. The “p53 Signalling Pathway” may regulate genes involved in DNA dam-
age and oxidative stress response. The experimentally validated target genes included in this pathway were: CDK2, 
CCNE246 and SESN1, stimulating proliferation, and ZMAT3, PMAIP1, SIAH1, and PTEN38, contributing to 
apoptosis or cell-cycle inhibitor. The “PI3K-Akt Signalling Pathway” is activated by many cellular stimuli or toxic 
insults and regulates fundamental cellular functions such as transcription, translation, proliferation, growth, and 
survival. The validated target genes are: BRCA1 and EIF4E2, promoting cells response to damage and hypoxia32,44; 
YWHAG, promoting a more mature phenotype in MSCs47, CDK2 and CCNE2, playing a role in cell cycle G1/S 
transition46; PTK2, promoting proliferation; ITGAV and PPP2R1B, promoting the TGF-beta signalling in both 
normoxia and hypoxia; PTEN, PPP2R5E, regulating the balance between survival and apoptosis; EFNA1, KDR 
and FLT1, encoding member of the vascular endothelial growth factor family38.
In the Profile A, we listed 11 down-regulated miRs, targeting 18 KEGG pathways. Interestingly, 2 relevant 
target pathways, the “TGF-beta Signalling Pathway” and “Signalling Pathways Regulating Pluripotency Of Stem 
Cells” are the same observed in the Profile BM, although these pathways, in Profile A, are regulated by different 
miRs. The validated target genes, included in “TGF-beta Signalling Pathway” in Profile A are: SP1, SMAD4 and 
RPS6KB1, which may promote a more mature and profibrotic phenotype in MSCs48,49 and RBL1, which may 
inhibit the cells proliferation by arresting the cells in G150. The validated target genes, included in “Signalling 
Pathways Regulating Pluripotency Of Stem Cells” are: JARID2, promoting more mature phenotype in MSCs; 
SMAD4, pro-fibrotic3,51; KAT6A and GSK3B, promoting cell proliferation52,53; MEIS1 and FZD1, promot-
ing senescence54,55 and KRAS, promoting cell survival56 and SMARCAD1, which may play a role during DNA 
Figure 2. Venn diagram. Venn diagram shows the numbers of miRs expressed in Profile BM (blue) and the 
numbers of miRs expressed in Profile A (red). The Profile BM and Profile A do not share any miRs expression.
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Profile BM 6 miR down-regulated KEGG pathways p-value genes miRs
1. Proteoglycans In Cancer (Hsa05205) 6,9e-05 40 5
2. Glioma (Hsa05214) 6,9e-05 18 5
3. Gap Junction (Hsa04540) 6,9e-05 22 6
4. Biotin Metabolism (Hsa00780) 0,0002 1 1
5. Erbb Signalling Pathway (Hsa04012) 0,0003 24 5
6. Renal Cell Carcinoma (Hsa05211) 0,0004 19 5
7. Neurotrophin Signalling Pathway (Hsa04722) 0,0005 31 5
8. Hepatitis B (Hsa05161) 0,002 30 6
9. Prostate Cancer (Hsa05215) 0,002 24 6
10. Phosphatidylinositol Signalling System (Hsa04070) 0,002 16 5
11. Glycosaminoglycan Biosynthesis - Chondroitin Sulfate / Dermatan Sulfate (Hsa00532) 0,004 3 2
12. Inositol Phosphate Metabolism (Hsa00562) 0,007 13 4
13. Lysine Degradation (Hsa00310) 0,007 9 4
14. Glycosphingolipid Biosynthesis - Lacto And Neolacto Series (Hsa00601) 0,009 5 2
15. Axon Guidance (Hsa04360) 0,009 26 3
16. Signalling Pathways Regulating Pluripotency Of Stem Cells (Hsa04550) 0,009 28 5
17. Chronic Myeloid Leukemia (Hsa05220) 0,01 19 5
18. Estrogen Signalling Pathway (Hsa04915) 0,01 19 6
19. Foxo Signalling Pathway (Hsa04068) 0,01 30 5
20. Thyroid Hormone Signalling Pathway (Hsa04919) 0,01 21 5
21. Pancreatic Cancer (Hsa05212) 0,01 17 5
22. MAPK Signalling Pathway (Hsa04010) 0,01 47 5
23. RNA Degradation (Hsa03018) 0,01 20 6
24. Acute Myeloid Leukemia (Hsa05221) 0,01 15 5
25. HIF-1 Signalling Pathway (Hsa04066) 0,01 23 6
26. Oocyte Meiosis (Hsa04114) 0,02 22 5
27. Endocytosis (Hsa04144) 0,02 37 5
28. TGF-Beta Signalling Pathway (Hsa04350) 0,02 15 4
29. Pathways In Cancer (Hsa05200) 0,02 66 6
30. P53 Signalling Pathway (Hsa04115) 0,03 16 4
31. PI3K-Akt Signalling Pathway (Hsa04151) 0,04 55 6
32. Melanoma (Hsa05218) 0,04 17 5
Profile BM 4 miR up-regulated KEGG pathway p-value genes miRs
1. ECM-Receptor Interaction (Hsa04512) 2,1 e-11 10 2
Profile A 11 miR down-regulated KEGG pathways p-value genes miRs
1. TGF-Beta Signalling Pathway (Hsa04350) 2,0E-05 21 8
2. Foxo Signalling Pathway (Hsa04068) 1,1E-03 38 9
3. Signalling Pathways Regulating Pluripotency Of Stem Cells (Hsa04550) 1,1E-03 36 10
4. Regulation Of Actin Cytoskeleton (Hsa04810) 7,9E-03 55 10
5. Thyroid Hormone Signalling Pathway (Hsa04919) 7,9E-03 26 10
6. Amphetamine Addiction (Hsa05031) 1,0E-02 18 9
7. Estrogen Signalling Pathway (Hsa04915) 1,0E-02 27 10
8. Choline Metabolism In Cancer (Hsa05231) 1,2E-02 29 10
9. Erbb Signalling Pathway (Hsa04012) 1,4E-02 25 9
10. Ras Signalling Pathway (Hsa04014) 1,6E-02 48 10
11. Thyroid Hormone Synthesis (Hsa04918) 1,9E-02 14 9
12. Ubiquitin Mediated Proteolysis (Hsa04120) 2,3E-02 32 10
13. Proteoglycans In Cancer (Hsa05205) 2,3E-02 44 10
14. Wnt Signalling Pathway (Hsa04310) 3,3E-02 30 10
15. Axon Guidance (Hsa04360) 3,5E-02 29 10
16. Prolactin Signalling Pathway (Hsa04917) 3,7E-02 19 8
17. Insulin Signalling Pathway (Hsa04910) 3,7E-02 35 10
Continued
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repair38. Some down-regulated miRs, in Profile A, target specific pathways, which have not been identified in 
Profile BM. “The Regulation Of Actin Cytoskeleton”, involving the validated target gene: ARPC5, ITGA5, WASF2, 
ACTN1, GIT1, IQGAP1 and DIAPH1 promoting actin cytoskeleton reorganization for cell invasion; PAK2/7, 
FGF9, PPP1CC and KRAS, promoting proliferation38, migration, and survival42,56, and of note, the target gene 
PAK2, promoting the cellular survival, was shared between BM- and A-MSCs. The “Wnt Signalling Pathway” 
including the validated genes: CHD8, GSK3B, TBL1XR1 and CCND2, promoting proliferation, migration and 
invasion; FZD1, promoting senescence; CSNK1A1, promoting self-renewal; and SMAD4 promoting a more 
mature phenotype in MSCs and SENP2, that may contribute to escape to TGF-beta signalling and PRKACA a 
survival kinase38.
Recently, it has been reported that perivascular cells, overexpressing the isoform 12 of A Disintegrin And 
Metalloprotease (ADAM12), play a role during fibrotic stimuli, trans-differentiating toward activated myofibro-
blast. Genetic ablation of ADAM12+ cells may limit the generation of profibrotic cells57. In previous work, we 
provide evidence of activated ADAM12 expression, in BM-SSc-MSC, suggesting their commitment toward a 
profibrotic activity16. Interestingly, we found that ADAM12 may be putatively targeted by several miRs (miR-
200b-3p, -642a-5p, 483-3p, 519b-3p, -10b-3p, -629-3p, -432-5p, -668-ep in the BM profile; miR-135b-5p, -204-
5p, -155-5p in the A profile), speculating that this miRs may play a role in overexpression of profibrotic gene 
ADAM12 in SSc-MSCs and driving these cells to a profibrotic fate.
In conclusion, the comparison of miR profiles of MSCs isolated from BM and A-tissue obtained from SSc 
patients, identified 2 different signatures and sharing similar functional alterations. The in silico prediction 
showed that both the BM- and A-MSCs display a similar senescent and profibrotic signature. Interestingly, both 
the MSCs source showed increased activity of the pathways related to survival ability and activation of compen-
satory mechanism, and these pathways may help MSCs to survive under the pathological constraints specific of 
the disease, without reverse the profibrotic phenotype, but this in silico approach is not able to define a hierarchy 
among these pathways and further studies need to define this setting. It must be pointed out that among the 
validated genes, potentially up-regulated in these cells, there are some genes involved in the angiogenic mech-
anisms. The activation of these genes may be involved in the improvement of the vascular conditions observed 
in the clinical trials, after infusion of these cells in SSc patients. In addition, “TGF-beta Signalling Pathway” is 
potentially up-regulated in both BM- and A-SSc-MSCs, correlating with previous work suggesting an activation 
of this pathway during SSc20,30. It has been showed that the increase of TGF-beta in SSc-MSCs may stimulate 
fibrotic process and also promote Tregs induction20, however future studies are ongoing in order to confirm the 
involvement of these down-regulated miRs in controlling TGF-beta function. In fact, the limitation of any in 
silico study is that the gene target interaction is a bioinformatics prediction, but it is the first necessary step, to 
select the potential genes, before starting focused experiments, thus restricting the field of interest and saving 
from unnecessary experiments. Further studies are ongoing in our laboratory to evaluate in vitro the ability of 
dysregulated miRs, to modulate the expression of the gene target and to evaluate the biological impact of this 
miRs on therapeutic function of SSc-MSCs. However, the main benefit of this in silico approach is the possibil-
ity to analyse all the identified miRs as a group, more than considering these molecules, separately, providing a 
larger vision of the biological pathways induced by the whole signature and give an integrated representation of 
the possible functional differences between BM- and A-MSCs. This bioinformatics approaches substantiate the 
concept of disease inherent abnormalities of SSc-MSCs, suggesting that these cells might contribute to the disease 
progression, as already reported in previous papers3,22,23. From a translational point of view, a better knowledge 
of MSCs signature, might allow us, in the future, to better select and potentially manipulate the MSCs to improve 
the development of MSC-based therapy for SSc.
Methods
All methods were performed in accordance with the relevant guidelines and regulations.
Patients, controls. We enrolled in this study 6 SSc patients, with a very similar clinical pattern. All patients 
fulfilled the 2013 classification criteria for SSc58. Our patients fulfilled the classification criteria in less than one 
year from the onset of Raynaud’s Phenomenon (RP). All SSc patients underwent 20-day washout from any immu-
nosuppressive treatment and one month from intravenous prostanoids. During this period, only proton-pump 
inhibitors and clebopride were allowed. Patients who could not undergo therapeutic washout, due to severe 
organ complications, were not enrolled in the study. The study was approved by our local ethics committee (ASL 
Avezzano Sulmona L’Aquila, protocol number 1092). Demographic and clinical characteristics of the patients are 
showed in Table 1.
Isolation, culture and immunophenotyping of BM-MSCs. After approval of local ethics committee 
(ASL Avezzano Sulmona L’Aquila n.1092) and written informed consent from patients, the BM was obtained by 
aspiration from the posterior superior iliac crest from 3 out of the 6 patients enrolled in the study. Three frozen 
Profile BM 6 miR down-regulated KEGG pathways p-value genes miRs
18. Neurotrophin Signalling Pathway (Hsa04722) 4,7E-02 29 9
Profile A 3 miR up-regulated KEGG pathway p-value genes miRs
1. Thyroid Hormone Signalling Pathway (Hsa04919) 6,9E-03 6 2
Table 3. KEGG pathways. KEGG pathways involving the dysregulated miRs. The p-value was calculated by 
DIANA miRPath v.3 software.
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BM-MSCs samples obtained from age- and sex- matched healthy donors (HC) were purchased from Lonza (USA) 
and used as control. Samples were placed into tubes containing ethylenediamine tetra acetic acid (EDTA) and the 
BM cells were obtained by density gradient sedimentation on 12% hydroxyethyl amide. The upper phase was har-
vested, centrifuged at 700 g for 10 min and plated at a concentration of 5 × 103 cells/cm2 in Dulbecco’s modified 
Profile BM (miR down-regulated):
hsa-miR-
200b-3p
hsa-miR-
519a-3p,
hsa-miR-
483-3p
Signalling Pathways Regulating 
Pluripotency Of Stem Cells (Hsa04550)
SMAD2/5
KLF4
MAPK Signalling Pathway (Hsa04010)
CRKL HSPA8 ZAK
RASA2
ELK4
PAK2
TAOK1
JUN
RPS6KA3
RAP1B
DUSP1
HIF-1 Signalling Pathway (Hsa04066)
PLCG1
FLT1
EIF4E2
TGF-Beta Signalling Pathway (Hsa04350)
SMAD2/5
PPP2R1B
P53 Signalling Pathway (Hsa04115)
ZMAT3 PTEN
CDK2
PMAIP1
CCNE2
SESN1
SIAH1
PI3K-Akt Signalling Pathway (Hsa04151)
PPP2R5E PTEN
YWHAG
CCNE2
CDK2
BRCA1
EIF4E2
PTK2
ITGAV
PPP2R1B
EFNA1
KDR
FLT1
Profile A (miRs down-regulated): hsa-miR-155-5p
hsa-miR-
500a-5p
hsa-miR-
146a-5p
hsa-miR-
146b-5p
hsa-miR-
204-5p
hsa-miR-
423-5p
hsa-miR-
135b-5p
hsa-miR-
218-5p
hsa-miR-
199b-5p
hsa-miR-
708-5p
TGF-Beta Signalling Pathway (Hsa04350)
SP1 RPS6KB1 RBL1 RBL1
SMAD4
Signalling Pathways Regulating 
Pluripotency Of Stem Cells (Hsa04550)
JARID2 SMAD4 FZD1 SMARCAD1
GSK3B MEIS1
KAT6A
KRAS
Regulation Of Actin Cytoskeleton 
(Hsa04810)
PAK2 ARPC5 ARPC5 WASF2 PPP1CC GIT1 IQGAP1
PAK7 ITGA5 ACTN1 DIAPH1
KRAS
FGF9
Wnt Signalling Pathway (Hsa04310)
GSK3B TBL1XR1 SMAD4 CCND2 PRKACA SENP2
CHD8 FZD1
CSNK1A1
Table 4. Gene interactions experimentally validated. The genes target experimentally validated of the down-
regulated miRs.
9Scientific RepoRts |          (2019) 9:7144  | https://doi.org/10.1038/s41598-019-43638-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
Eagle’s medium (DMEM; Gibco, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, USA), 2 mmol/l 
L-glutamine (EuroClone, Italy) and 100 U penicillin, 1000 U streptomycin (Biochrom AG, Germany). Both SSc 
and healthy control (HC) cultures were grown and expanded in flasks at 37 °C, 5% CO2 in a humidified thermo-
stat for 2 weeks until confluence and used for the following experiments at third passage (P3). The International 
Society for Stem Cell Therapy (ISCT) drew the surface antigen pattern for defining MSCs59. According, the P3 
isolated cells were analyzed for the surface antigen by flow cytometry (FACSCAN, Becton Dickinson, USA), to 
assess their purity (CD105, CD73 and CD90 > 95% positive and CD34-, CD45-, CD14-, CD79-, HLA class II 
(DR) ≤ 2% positive). This assessment was done concurrently with miRs evaluation.
Isolation, culture and immunophenotyping of A-MSCs. Adipose tissue was obtained from the other 
3 patients enrolled in the study, after approval of local ethics committee (ASL Avezzano Sulmona L’Aquila n.1092) 
and written informed consent from patients. Three frozen A-MSCs samples obtained from age- and sex- matched 
healthy donors (HC) were purchased from Lonza (USA) and used as control. Lipoaspirate (500 mg) was washed 
to remove excess blood by mixing with an equal volume of phosphate-buffered saline (PBS; Euroclone, Italy). 
The fat is placed in a sterile tissue culture plate with 0.075% Collagenase Type I prepared in PBS containing 
2% P/S for tissue digestion (lysis buffer). Furthermore, the pellet, containing the A-MSCs, was obtained by 
centrifuging the sample at 2000 rpm for 5 min. After spinning, all the collagenase solution was aspirated, and 
the pellet resuspended in 1 ml lysis buffer, incubated for 10 min on ice, washed with 20 ml of lysis buffer and 
centrifuged at 2000 rpm for 5 min. The cell pellet was resuspended in a maximum of 3 ml of stromal medium 
(DMEM + 20%FBS + glutamine + penicillin/streptomycin), the cell suspension is filtered through 70 μm cell 
strainer and incubate at 37 °C with 5% humidified CO2. The outgrown cells were cultured in fresh medium for 
another 7–10 days until a confluent monolayer was obtained.
These initial cells, referred to as passage 1 (P1), were further sub-cultured at a seeding density of 100–500 
cells/cm2 and serially passaged in a humidified thermostat for 2 weeks until confluence and used for the following 
experiments at third passage (P3). The P3 isolated cells were analyzed for the surface antigen by flow cytometry 
(FACSCAN, Becton Dickinson, USA), to assess their purity (CD105, CD73 and CD90 > 95% positive and CD34-, 
CD45-, CD14-, CD79-, HLA class II (DR) ≤ 2% positive). This assessment was done concurrently with miRs 
evaluation.
MiRs profiling. Total RNAs were extracted from P3-MSCs using the mirVana miRs isolation kit (Ambion, 
Thermo Fisher Scientific, USA) by following the manufacturer’s instructions. RNA concentrations and qualities 
were evaluated by using NanoDrop 2000 (Thermo scientific, USA). Total RNA samples, containing the fraction 
less than 200 nucleotides, were used for miRs profiling studies. Identical amounts of RNAs extracted from each 
patient and healthy control were pooled together and subjected (700 ng per RNAs’ pool) to qRT-PCR by using the 
TaqMan MicroRNA reverse transcription kit (Applied Biosystems, USA) and the Megaplex RT primers human 
pool (Applied Biosystems, USA). Subsequently, microfluidic cards TaqMan array human microRNA A + B v3.0 
(Applied Biosystems, USA) were used, according to the manufacturer’s instructions. Three replicates for each 
pooled sample were analysed. MiRs’ expression levels were evaluated by comparative assay: samples were ana-
lysed on a ViiA7 (Applied Biosystems, USA) and data were processed by ViiA7 software and further elaborated 
by Expression Suite (v.1.0.3, Applied Biosystems, USA) also at the statistical level. 2−ΔΔCt method was used to 
Figure 3. Graphical visualization of miRNA-target interactions. Neo4J software graphical visualization 
of miRNA-target interactions, concerning the Profile BM (left) and Profile (right) A. Red circles represent 
miRNAs. Blue circles represent genes that interact with the miRs, experimentally supported in TarBase. Purple 
circles represent the relevant pathways, that include validated target genes. Both the Profile BM and Profile A 
share “TGF-beta Signalling Pathway” and “Signaling Pathways Regulating Pluripotency Of Stem Cells”.
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determine the relative miRs’ expression levels. U6 snRNA was used as endogenous control. Significant miRs 
expression changes were identified using a threshold of p < 0.05 (p value calculation based on 2−dCt).
Pathway analysis and target gene prediction. To gain insight into the biological function of these 
miRs, we performed bibliographic research and a more global approach based on in silico analysis. To achieve 
this, we used the DIANA miRPath v.3 software, which is a web-based computational tool, provided by http://
diana.cslab.ece.ntua.gr/pathways/ 60 and designed to predict the miRs target genes.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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